Clinical Trial Results: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) [Phase 3]

View source ↗

Summary

Phase 3 trial results for Veligrotug (VRDN-001) in chronic thyroid eye disease evaluated efficacy, safety, and tolerability; study completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• Veligrotug (VRDN 001)

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-08-13